FindTrial
Sign In

Validation of Anti-Phospholipase A2 Receptor Antibody ELISA in a Chinese Cohort With Idiopathic Membranous Nephropathy: a Multicenter Observational Study

The Cut-off Value of Anti-Phospholipase A2 Receptor Antibody ELISA in Chinese Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027128
Enrollment
Unknown
Registered
2019-11-01
Start date
2019-10-30
Completion date
Unknown
Last updated
2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Membranous Nephrology

Interventions

Gold Standard:Pathological diagnosis according to kidney biopsy(Chapter 7, 7.1 Evaluation of MN, KDIGO 2012)
Index test:Serum&#32
PLA2R&#32
Antibody&#32
by&#32
ELISA

Sponsors

Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosised with glomerular nephropathy according to kidney biopsy

Exclusion criteria

Exclusion criteria: 1. Patients who received immunosuppressive treatment; 2. Patients with incomplete information.

Design outcomes

Primary

MeasureTime frame
PLA2R antibody;—

Secondary

MeasureTime frame
urine protein quantitation;—

Countries

China

Contacts

Public ContactYipeng Liu

Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China

liuyipeng@sdhospital.com.cn+86 13064089262

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026